Apillet to participate in the BioFit partnering conference December 11 – 13, 15, 2023 Apillet is represented by CEO Anders Christensen at the BioFit partnering conference in Marseille FR. Apillet is giving a business pitch session. The pitch is given on the 13th of December the second day of the conference. The pitch will present […]
Apillet to participate in the BioFit partnering conference Read More »
Apillet has been granted its first national patents Company announcement 06/2023. Roskilde, September 27. 2023 We are thrilled to announce the decission by the European Patent Office to grant Apillet a European Patent with the title Novel Oral Composition. The decision will take effect on October 4. 2023, when the mention of the grant is
Apillet has been granted its first national patents Read More »
Apillet participates in FBHC 2023 Company announcement 5/2023. Roskilde, September 19. 2023 Apillet participates in FBHC 2023 – 4th International Conference on Food Bioactives & Health. CEO Anders Christensen is participating in FBHC 2023 September 18-21 in Prague and promoting our gastro-resistant enteric encapsulation technologies looking for investors / financing, for clients and partners and for
Apillet participates in FBHC 2023 Read More »
Apillet has identified the first intestinal delivery targets for the APIVault encapsulation Company announcement 04/2023. Roskilde, May 19. 2023 Apillet ApS today announces the first intestinal delivery targets for its APIVault enteric encapsulation material for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals. APIVault is a breakthrough encapsulation material made entirely from natural ingredients: bacterial
The release properties of Apillets combo-material APIVault shows a high degree of reproducibility Company announcement 03/2023. Roskilde, April 28. 2023 Apillet has further studied the design factors that governs the release onset of the APIVault encapsulation. Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics
Apillet has identified a commercially available cellulase for its APIVault encapsulation Company announcement 02/2023. Roskilde, April 11. 2023 Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of a commercially available cellulase for its APIVault encapsulation material. We are
Apillet has identified a commercially available cellulase for its APIVault encapsulation Read More »
Apillet has identified Commercially available Bacterial celluloses for our BC-Combo-material Company announcement 01/2023. Roskilde, March 16. 2023 Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of Commercially available bacterial cellulose for its APIVault encapsulation material. The APIVault encapsulation
Apillet participated in the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods Roskilde October 5, 2022 CEO Anders Christesen presented the talk ”The development of an enteric capsule made from natural materials for oral delivery of Probiotics / Nutraceuticals” at the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October
Apillet ApS Announces in-vitro testing of APIVault tablet Prototype Company announcement 01/2022 Roskilde, 10.06.2022 Apillet ApS Announces the in-vitro testing of APIVault tablet Prototype. Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the first prototype of the APIVault enteric technology for targeted
Apillet ApS Announces in-vitro testing of APIVault tablet Prototype Read More »
Apillet has identified Commercially available Bacterial celluloses for our BC-Combo-material Company announcement 01/2023. Roskilde, March 16. 2023 Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the identification of Commercially available bacterial cellulose for its APIVault encapsulation material. The APIVault encapsulation